Clinical Efficacy of Montelukast Combined with Mometasone Furoate Nasal Spray in the Treatment of Pa-tients with Allergic Rhinitis
- VernacularTitle:孟鲁司特钠联合糠酸莫米松鼻喷雾剂治疗过敏性鼻炎的疗效观察
- Author:
Yincun YE
;
Peifang JIANG
- Publication Type:Journal Article
- Keywords:
Montelukast;
Mometasone furoate nasal spray;
Allergic rhinitis
- From:
China Pharmacist
2016;19(10):1911-1913
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of montelukast combined with mometasone furoate in the treat-ment of children with allergic rhinitis. Methods:Totally 91 children with allergic rhinitis were randomly divided into the observation group (n=46) and the control group (n=45) according to the random number table. The control group was given mometasone fu-roate, while the observation group was treated with montelukast additionally. Both groups were treated for two weeks. The symptom scores including nasal congestion, sneezing, itchy nose and runny nose, serum level changes of IL-4, IL-12 and IgE and adverse drug reactions before and after the treatment in both groups were evaluated and compared. Results:The total effective rate in the observation group (93. 48%) was significantly higher than that in the control group (75. 56%, P<0. 05). Compared with those before the treat-ment, the symptom scores in both groups were decreased after the treatment (P<0. 05), and those in the observation group were lower than those in the control groups (P<0. 05). After the treatment, the serum levels of IL-4 and IgE in both groups were significantly de-creased when compared with those before the treatment, while the IL-12 levels were increased significantly (P<0. 05), and the chan-ges in the observation group were more significantl than those in the control group (P<0. 05). There were no serious adverse drug re-actions during the treatment course in both groups. Conclusion:Montelukast combined with mometasone furoate in the treatment of al-lergic rhinitis shows more notable efficacy with higher security.
